RIVASTIGMINE

N/A

Manufactured by Sandoz Inc

39,624 FDA adverse event reports analyzed

Last updated: 2026-04-14

About RIVASTIGMINE

RIVASTIGMINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Sandoz Inc. The most commonly reported adverse reactions for RIVASTIGMINE include DEATH, FALL, HALLUCINATION, CONFUSIONAL STATE, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RIVASTIGMINE.

Top Adverse Reactions

DEATH2,177 reports
FALL1,664 reports
HALLUCINATION1,366 reports
CONFUSIONAL STATE1,258 reports
DRUG INEFFECTIVE896 reports
VOMITING884 reports
NAUSEA826 reports
DIZZINESS771 reports
GAIT DISTURBANCE713 reports
PNEUMONIA688 reports
MALAISE649 reports
SOMNOLENCE645 reports
DIARRHOEA640 reports
FATIGUE637 reports
URINARY TRACT INFECTION610 reports
ASTHENIA609 reports
CONDITION AGGRAVATED584 reports
WEIGHT DECREASED575 reports
TREMOR571 reports
PARKINSON^S DISEASE567 reports
MEMORY IMPAIRMENT564 reports
DEMENTIA548 reports
GENERAL PHYSICAL HEALTH DETERIORATION547 reports
OFF LABEL USE533 reports
AGITATION527 reports
AGGRESSION513 reports
DECREASED APPETITE493 reports
INSOMNIA446 reports
CEREBROVASCULAR ACCIDENT445 reports
COGNITIVE DISORDER425 reports
DYSPHAGIA419 reports
DYSKINESIA409 reports
DYSPNOEA397 reports
HYPOTENSION391 reports
DRUG INTERACTION385 reports
ANXIETY384 reports
HALLUCINATION, VISUAL380 reports
SYNCOPE375 reports
CONSTIPATION372 reports
DEHYDRATION356 reports
LOSS OF CONSCIOUSNESS356 reports
ABNORMAL BEHAVIOUR352 reports
DISORIENTATION345 reports
SPEECH DISORDER335 reports
MOBILITY DECREASED324 reports
ON AND OFF PHENOMENON317 reports
DELIRIUM306 reports
HYPERTENSION305 reports
BALANCE DISORDER303 reports
FEELING ABNORMAL303 reports
DEPRESSION302 reports
DEMENTIA ALZHEIMER^S TYPE300 reports
HEADACHE291 reports
PYREXIA290 reports
DELUSION282 reports
BRADYCARDIA275 reports
PAIN272 reports
PRODUCT ADHESION ISSUE270 reports
MUSCLE RIGIDITY265 reports
APPLICATION SITE ERYTHEMA261 reports
RESTLESSNESS257 reports
PRODUCT DOSE OMISSION ISSUE256 reports
FREEZING PHENOMENON233 reports
PRURITUS232 reports
RASH224 reports
ANAEMIA221 reports
MUSCULOSKELETAL STIFFNESS218 reports
ABDOMINAL PAIN213 reports
CARDIAC ARREST201 reports
HYPERHIDROSIS200 reports
BRADYKINESIA198 reports
APPLICATION SITE PRURITUS188 reports
ERYTHEMA188 reports
UNEVALUABLE EVENT188 reports
HIP FRACTURE187 reports
MUSCULAR WEAKNESS187 reports
BLOOD PRESSURE INCREASED186 reports
STOMA SITE DISCHARGE186 reports
PNEUMONIA ASPIRATION181 reports
DEVICE ISSUE178 reports
PAIN IN EXTREMITY176 reports
MYOCARDIAL INFARCTION174 reports
HYPOPHAGIA172 reports
OEDEMA PERIPHERAL170 reports
PRODUCT USE IN UNAPPROVED INDICATION167 reports
APHASIA166 reports
RENAL FAILURE166 reports
AMNESIA161 reports
URINARY INCONTINENCE161 reports
SLEEP DISORDER160 reports
DEMENTIA ALZHEIMER'S TYPE159 reports
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS158 reports
INFECTION156 reports
DEVICE DISLOCATION155 reports
DISTURBANCE IN ATTENTION155 reports
OVERDOSE154 reports
ACUTE KIDNEY INJURY152 reports
CARDIAC FAILURE150 reports
COUGH149 reports
SEPSIS148 reports

Report Outcomes

Out of 17,977 classified reports for RIVASTIGMINE:

Serious 84.7%Non-Serious 15.3%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female8,644 (51.0%)
Male8,287 (48.9%)
Unknown25 (0.1%)

Reports by Age

Age 78556 reports
Age 76528 reports
Age 83491 reports
Age 82481 reports
Age 79476 reports
Age 80476 reports
Age 75464 reports
Age 84447 reports
Age 77444 reports
Age 81435 reports
Age 74366 reports
Age 73358 reports
Age 85358 reports
Age 87329 reports
Age 72328 reports
Age 86327 reports
Age 70323 reports
Age 88297 reports
Age 71260 reports
Age 69239 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with RIVASTIGMINE?

This profile reflects 39,624 FDA FAERS reports that mention RIVASTIGMINE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for RIVASTIGMINE?

Frequently reported terms in FAERS include DEATH, FALL, HALLUCINATION, CONFUSIONAL STATE, DRUG INEFFECTIVE, VOMITING. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures RIVASTIGMINE?

Labeling and FAERS entries often list Sandoz Inc in connection with RIVASTIGMINE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.